RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.
Flores-Pérez A, Rafaelli LE, Ramírez-Torres N, Aréchaga-Ocampo E, Frías S, Sánchez S, Marchat LA, Hidalgo-Miranda A, Quintanar-Jurado V, Rodríguez-Cuevas S, Bautista-Piña V, Carlos-Reyes A, López-Camarillo C.
Flores-Pérez A, et al. Among authors: ramirez torres n.
Cancer Biol Ther. 2014 Jun 1;15(6):777-88. doi: 10.4161/cbt.28551. Epub 2014 Mar 18.
Cancer Biol Ther. 2014.
PMID: 24642965
Free PMC article.